ClinicalTrials.gg
Not yet recruitingNCT07858695Updated Nov 13, 2026

Barber and Pharmacist Coordination to Improve Blood Pressure Management

An interventional study of Telemedicine Barbershop BP Reduction in Antihypertensive Agents, High Blood Pressure and Hypertension, sponsored by Cedars-Sinai Medical Center. Not yet recruiting at 1 site in United States. Open to male participants aged 35 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
35 Years to 79 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by Cedars-Sinai Medical Center — 1 open to participants now, 1 under way, none of them phase 3. Hypertension · Cedars-Sinai Medical Center.

Planned enrollment
4th of 12
55 · median 40
Started
2026
the only one that year
No phase
9 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Hypertension by Cedars-Sinai Medical Center, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 14th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 14 studies in Hypertension by Cedars-Sinai Medical Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 35 Years to 79 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by Cedars-Sinai Medical Center, or all of them as a file.
02

Study summary

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Read the detailed description

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged.

The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men". The goal of the study is to build upon the foundational work of the original study and adapt the in-person clinical pharmacist-led LABBPS hypertension (HTN) management program into a complete telemedicine version and assess feasibility, acceptability, effectiveness, and implementation considerations of the adaptation to inform future scale-up. We will design and test the impact of barber assisted hypertension screening combined with clinical pharmacist-led hypertension management delivered via a secure video platform among 55 men from 10 barbershops. Participants will be age 35-79 years with stage 2 hypertension defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg. This diverse age group was chosen because current guidelines recommend initiation of antihypertensive medications for stage 2 hypertension regardless of baseline cardiovascular risk. In addition to using validated implementation science frameworks to measure feasibility and acceptability, the study will also quantify effectiveness by comparing changes in blood pressure at 6-months to those achieved in the original in-person intervention.

Hypertension (HTN) is an exceptionally common condition that imposes a substantial public health burden and disproportionately impacts non-Hispanic (NH) Black men. The Barber and Pharmacist Coordination to Improve Blood Pressure Management Study builds upon the foundational work of the Los Angeles Barbershop BP Study (ClinicalTrials.gov ID: NCT02321618) and seeks to develop a less costly and more convenient telemedicine version of pharmacist-driven, community-based hypertension care for black men that will enable widespread adoption of this healthcare model across barbershops nationwide. While the barbershop-based approach has demonstrated success in non-Hispanic black men, the benefits may well extend to other racial and ethnic populations who frequent community- based venues. Increasing adoption of community-based interventions and enabling supportive healthcare policies requires the demonstration of a financially feasible model and durable impact on clinical outcomes.

03

Conditions studied

  • Antihypertensive Agents
  • High Blood Pressure
  • Hypertension

Browse trials for

Keywords

  • Barbershop
  • Pharmacist
  • African American Men
  • High Blood Pressure
  • Hypertension
  • Telemedicine
  • Team-Based Care
04

Who can participate

Ages eligible
35 Years to 79 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 35-79
  2. Self-identify as NH Black male
  3. Documented systolic BP ≥ 140 mmHg on 2 or more separate screening days. The second BP assessment must be completed within a 4-week period
  4. Regularly attend the same barbershop (barbershop patrons having at least one haircut every 6 weeks in the same barbershop for the past 6 months)
  5. Signed physician collaborative practice agreement with the study pharmacist

Exclusion criteria

Exclusion Criteria:

  1. Ages \<35 or >79 years
  2. Arm circumference incompatible with the BP device
  3. Severe cognitive impairment
  4. Non-fluent in English
  5. Currently receiving chemotherapy for cancer
  6. Current or planned cardiac, renal, or liver transplant
  7. Currently receiving dialysis
  8. New/infrequent patronage (\<8 haircuts at the same barbershop in the past 12 months)
  9. Plans to move/relocate in the next 12 months and/or travel out-of-area for > 1 month
  10. Participation in a clinical trial where the active treatment study is testing a BP agent and/or intervention
  11. Unwilling or unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Interventions

  • OtherTelemedicine Barbershop BP Reduction

    Test feasibility, acceptability, and effectiveness of an adapted blood pressure reduction intervention that moves the LABBPS in-person clinical pharmacist to a telemedicine platform inside of the barbershop.

06

What researchers measure

Primary outcomes

  1. Change in Systolic Blood Pressure (SBP)

    The primary outcome will be the difference in SBP measured at 6 months compared to enrollment.

    Time frame: 6 months

Secondary outcomes

  1. Change in Diastolic Blood Pressure (DBP)

    1. Difference in DBP measured at 6 months compared to enrollment 2. Achievement of goal BP, 6 months, Proportion of participants achieving SBP \<130 mm Hg AND DBP \<80 mm Hg 3. Medication Intensification, 6 months, Difference in the number of BP drugs of different classes at 6 months compared to enrollment 4. First-line medication use, 6 months, Difference in percentage of participants receiving first-line BP drug classes at 6 months compared to enrollment 5. Recruitment and retention rates will be quantified to assess feasibility 6. Acceptability to barbers and participants

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, Brettler J, Rashid M, Hsu B, Foxx-Drew D, Moy N, Reid AE, Elashoff RM. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. N Engl J Med. 2018 Apr 5;378(14):1291-1301. doi: 10.1056/NEJMoa1717250. Epub 2018 Mar 12. PubMed 29527973 ↗
  • Victor RG, Blyler CA, Li N, Lynch K, Moy NB, Rashid M, Chang LC, Handler J, Brettler J, Rader F, Elashoff RM. Sustainability of Blood Pressure Reduction in Black Barbershops. Circulation. 2019 Jan 2;139(1):10-19. doi: 10.1161/CIRCULATIONAHA.118.038165. PubMed 30592662 ↗
  • Blyler CA, Rader F. Sustainability of blood pressure reduction in black barbershops. Curr Opin Cardiol. 2019 Nov;34(6):693-699. doi: 10.1097/HCO.0000000000000674. PubMed 31425171 ↗
  • Blyler CA, Ebinger J, Rashid M, Moy NP, Cheng S, Albert CM, Rader F. Improving Efficiency of the Barbershop Model of Hypertension Care for Black Men With Virtual Visits. J Am Heart Assoc. 2021 Jul 6;10(13):e020796. doi: 10.1161/JAHA.120.020796. Epub 2021 Jun 22. PubMed 34155907 ↗
  • Bryant KB, Moran AE, Kazi DS, Zhang Y, Penko J, Ruiz-Negron N, Coxson P, Blyler CA, Lynch K, Cohen LP, Tajeu GS, Fontil V, Moy NB, Ebinger JE, Rader F, Bibbins-Domingo K, Bellows BK. Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. Circulation. 2021 Jun 15;143(24):2384-2394. doi: 10.1161/CIRCULATIONAHA.120.051683. Epub 2021 Apr 15. PubMed 33855861 ↗
  • Kazi DS, Wei PC, Penko J, Bellows BK, Coxson P, Bryant KB, Fontil V, Blyler CA, Lyles C, Lynch K, Ebinger J, Zhang Y, Tajeu GS, Boylan R, Pletcher MJ, Rader F, Moran AE, Bibbins-Domingo K. Scaling Up Pharmacist-Led Blood Pressure Control Programs in Black Barbershops: Projected Population Health Impact and Value. Circulation. 2021 Jun 15;143(24):2406-2408. doi: 10.1161/CIRCULATIONAHA.120.051782. Epub 2021 Jun 14. No abstract available. PubMed 34125566 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Apr 30, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: design details
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858695
Responsible party
Christine Albert (Principal Investigator, Cedars-Sinai Medical Center) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Ciantal Adair Blyler, PharmD
Contact
ciantel.blyler@cshs.org
310-248-7520
Julie Pester, BA
Contact
juliepester@cshs.org
310-248-7520
Christine Albert, MD, MPH
principal investigator · Brigham and Women's Hosptial

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion